Treatment of Advanced Non-Resectable, Non-Irradiable or Metastatic Thymoma (Masaoka-Koga Stage IVB)
Clinical Scenario
This protocol applies to patients with thymoma at Masaoka-Koga stage IVB — disease that is advanced, not amenable to surgical resection, not amenable to radiotherapy, or has spread to distant sites. In this setting, systemic treatment is the indicated management pathway.
Treatment Goals
The primary clinical aim is to relieve tumour-related symptoms through tumour shrinkage, with prolonged survival remaining an uncertain outcome. Response to treatment is evaluated using RECIST v1.1 criteria.
Treatment Approach
Chemotherapy serves as the single modality of treatment in this setting. A cisplatin-based combination regimen is the recommended systemic approach.
The complete regimen — including the preferred agent combination, dosing, schedule, and sequencing — is available in the full structured protocol.
References
DOI: 10.1093/annonc/mdv277
- Chemotherapy should be offered as single modality treatment in advanced, non-resectable, non-irradiable or metastatic (stage IVB) thymic epithelial tumours.
- Cisplatin-based combination regimens should be administered [III, A] (Table 6).
- Combination of cisplatin, doxorubicin and cyclophosphamide is preferred [III, B].
- The aim is to relieve tumour-related symptoms by eliciting tumour shrinkage, while prolonged survival is uncertain [III, A].
- Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 criteria should be used to assess response to chemotherapy [V, A].
View source ↗